JOP20210220A1 - معالجة الداء النشواني من النوع خفيف السلسلة بتوليفة من أجسام مضادة أحادية النسيلة ضد سلاسل الغلوبيولين المناعي الخفيفة وجزيء الغشاء الخلوي cd38 على خلايا مناعية منتجة للأجسام المضادة وخلايا مناعية أخرى - Google Patents

معالجة الداء النشواني من النوع خفيف السلسلة بتوليفة من أجسام مضادة أحادية النسيلة ضد سلاسل الغلوبيولين المناعي الخفيفة وجزيء الغشاء الخلوي cd38 على خلايا مناعية منتجة للأجسام المضادة وخلايا مناعية أخرى

Info

Publication number
JOP20210220A1
JOP20210220A1 JOP/2021/0220A JOP20210220A JOP20210220A1 JO P20210220 A1 JOP20210220 A1 JO P20210220A1 JO P20210220 A JOP20210220 A JO P20210220A JO P20210220 A1 JOP20210220 A1 JO P20210220A1
Authority
JO
Jordan
Prior art keywords
light chains
immunoglobulin light
amyloidosis
antibody
producing
Prior art date
Application number
JOP/2021/0220A
Other languages
English (en)
Inventor
Comenzo Raymond
Zago Wagner
Mercedes Ashton Nina
Original Assignee
Prothena Biosciences Ltd
Tufts Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Tufts Medical Ct Inc filed Critical Prothena Biosciences Ltd
Publication of JOP20210220A1 publication Critical patent/JOP20210220A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

يتعلق هذا الاختراع بمعالجة الداء النشواني من النوع خفيف السلسلة بتوليفة من أجسام مضادة أحادية النسيلة ضد سلاسل الغلوبيولين المناعي الخفيفة وتكتلات من سلاسل الغلوبيولين المناعي الخفيفة وجزيء الغشاء الخلوي CD38 على خلايا مناعية منتجة للأجسام المضادة وخلايا مناعية أخرى. الشكل 1.
JOP/2021/0220A 2019-02-12 2019-12-16 معالجة الداء النشواني من النوع خفيف السلسلة بتوليفة من أجسام مضادة أحادية النسيلة ضد سلاسل الغلوبيولين المناعي الخفيفة وجزيء الغشاء الخلوي cd38 على خلايا مناعية منتجة للأجسام المضادة وخلايا مناعية أخرى JOP20210220A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962804721P 2019-02-12 2019-02-12
PCT/US2019/066648 WO2020167376A1 (en) 2019-02-12 2019-12-16 Treatment of al amyloidosis with the combination of monoclonal antibodies against immunoglobulin light chains and the cd38 cell membrane molecule on antibody-producing and other immune cells

Publications (1)

Publication Number Publication Date
JOP20210220A1 true JOP20210220A1 (ar) 2023-01-30

Family

ID=69182616

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0220A JOP20210220A1 (ar) 2019-02-12 2019-12-16 معالجة الداء النشواني من النوع خفيف السلسلة بتوليفة من أجسام مضادة أحادية النسيلة ضد سلاسل الغلوبيولين المناعي الخفيفة وجزيء الغشاء الخلوي cd38 على خلايا مناعية منتجة للأجسام المضادة وخلايا مناعية أخرى

Country Status (16)

Country Link
US (1) US20220213223A1 (ar)
EP (1) EP3923954A1 (ar)
JP (1) JP2022520572A (ar)
KR (1) KR20210143752A (ar)
CN (1) CN113924099A (ar)
AU (1) AU2019429147A1 (ar)
BR (1) BR112021015870A2 (ar)
CA (1) CA3129890A1 (ar)
CL (1) CL2021002140A1 (ar)
EA (1) EA202192235A1 (ar)
IL (1) IL285480A (ar)
JO (1) JOP20210220A1 (ar)
MA (1) MA54923A (ar)
MX (1) MX2021009687A (ar)
SG (1) SG11202108767PA (ar)
WO (1) WO2020167376A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022522889A (ja) 2019-03-05 2022-04-20 プロシーナ バイオサイエンシーズ リミテッド Ａｌアミロイドーシスを処置する方法
IL300059A (en) 2020-07-23 2023-03-01 Othair Prothena Ltd Anti-Abata antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
EP2535355B1 (en) 2005-03-23 2019-01-02 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
AU2008345022B2 (en) 2007-12-28 2014-11-06 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
WO2011154453A1 (en) 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
KR102196009B1 (ko) 2011-10-25 2021-01-04 프로테나 바이오사이언시즈 리미티드 항체 제형 및 방법
US9364542B2 (en) 2011-10-28 2016-06-14 Excelse Bio, Inc. Protein formulations containing amino acids
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
MD3827845T2 (ro) 2015-11-03 2022-09-30 Janssen Biotech Inc Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
PT3478713T (pt) * 2016-06-30 2022-05-27 Prothena Biosciences Ltd Composições para tratamento da amiloidose

Also Published As

Publication number Publication date
BR112021015870A2 (pt) 2021-11-03
WO2020167376A1 (en) 2020-08-20
CL2021002140A1 (es) 2022-04-18
US20220213223A1 (en) 2022-07-07
CN113924099A (zh) 2022-01-11
CA3129890A1 (en) 2020-08-20
SG11202108767PA (en) 2021-09-29
AU2019429147A1 (en) 2021-09-09
KR20210143752A (ko) 2021-11-29
EP3923954A1 (en) 2021-12-22
EA202192235A1 (ru) 2022-01-19
WO2020167376A8 (en) 2020-10-29
MX2021009687A (es) 2021-12-10
IL285480A (en) 2021-09-30
MA54923A (fr) 2021-12-22
JP2022520572A (ja) 2022-03-31

Similar Documents

Publication Publication Date Title
EA202092945A1 (ru) Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии
IL285480A (en) Treatment of al amyloidosis in combination with monoclonal antibodies against immunoglobulin light chains and cell membrane molecule cd38 on antibody-producing cells and other immune system cells
WO2019074973A3 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
MX2019002268A (es) Anticuerpo monoclonal anti-pd1, composicion farmaceutica de este y uso de este.
MX2020005792A (es) Anticuerpo anti-pd-l1/anti-cd47 biespecifico con estructura tipo anticuerpo natural y en forma de heterodimero y preparacion del mismo.
DK1654286T3 (da) Humaniseret anti-CD4-antistof med immunsuppressive egenskaber
ATE452147T1 (de) Antikörper mit korrigierten cdr
EA202190608A1 (ru) Однодоменные анти-bcma антитела и их применение
MX2022001111A (es) Anticuerpo anti-pd-1 y uso farmaceutico del mismo.
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
MX2022002505A (es) Anticuerpo monoclonal anti-cd47 y uso del mismo.
MX2020010722A (es) Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.
MX2021015763A (es) Polipeptidos.
ZA202206670B (en) Anti-ly6g6d antibodies and methods of use
WO2018195457A3 (en) Routes and schedules for treating multiple sclerosis with anti-cd52 antibodies
WO2023051642A8 (en) Humanized anti-c5a antibodies and uses thereof
EA202092264A1 (ru) Лечение и профилактика амилоидоза
MX2021012652A (es) Metodos para el tratamiento de sujetos con artritis psoriasica.
MX2017016445A (es) Inmunoglobulinas ige e igg monoclonales e hibridoma para producir las mismas, para el diagnostico e inmunoterapia de reacciones de hipersensibilidad.
TH1801003246A (th) โพลีเปปไทด์ชนิดมีตำแหน่งยึดจับแอนติเจนสองแบบที่ลบล้างฤทธิ์การส่งสัญญาณ wnt ในเซลล์เนื้องอก
CY1115174T1 (el) Ενα μονοκλωνικο αντισωμα κατα cd44 για χρηση για την θεραπευτικη αντιμετωπιση καρκινωματος εκ πλακωδων κυτταρων της κεφαλης και του τραχηλου